Unicancer
Adeline Poitou serves as Cheffe de Projets en Etudes Cliniques at Unicancer since September 2023, following a five-year tenure as Clinical Study Coordinator in the UCGI Group within the same organization. Adeline's experience includes coordinating numerous phase II and III clinical studies, managing logistical and procedural aspects, and overseeing data reconciliation and monitoring activities. Prior roles encompass Clinical Research Associate II and Attachée de Recherche Clinique for UNITRAD and UCBG, focusing on data management and trial procedure development. Adeline's background in biotechnology engineering, coupled with internships in molecular biology and structural analysis, supports a robust expertise in clinical research methodologies and innovation in therapeutic development. Educational qualifications include degrees from Université de Technologie de Compiègne and Université Joseph Fourier, specialized in clinical research and biotechnology.
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries